Literature DB >> 31926872

Nationwide estimates of medication therapy management delivery under the Medicare prescription drug benefit.

Deborah L Pestka, Alan J Zillich, Antoinette B Coe, Karen B Farris, Omolola A Adeoye, Margie E Snyder, Joel F Farley.   

Abstract

OBJECTIVE: To describe the national delivery of medication therapy management (MTM) to Medicare beneficiaries in 2013 and 2014.
METHODS: Descriptive cross-sectional study using the 100% sample of 2013 and 2014 Part D MTM data files. We quantified descriptive statistics (counts and percentages, in addition to means and standard deviations) to summarize the delivery of these services and compare delivery between 2013 and 2014.
RESULTS: Medicare beneficiaries eligible for MTM increased from 4,281,733 in 2013 to 4,552,547 in 2014. Among eligible beneficiaries, the number and percentage who were offered a comprehensive medication review (CMR) increased from 3,473,004 (81.1%) to 4,394,822 (96.5%), and beneficiaries receiving a CMR increased from 526,203 (12.3%) to 767,286 (16.9%). In 2014, CMRs were most frequently delivered by telephone (83.2%) and provided by either a plan sponsor (29.0%) or an MTM vendor in-house pharmacist (35.0%). In 2014, pharmacists provided 93.5% of all CMRs, and other providers (e.g., nurses and physicians) provided 6.5% of CMRs. Few patients who received a CMR received more than 1 within the same year (2.2% in 2014). Medication therapy problem (MTP) resolution among patients receiving a CMR stayed roughly the same between 2013 and 2014 (19.2% vs. 18.7%, respectively; P < 0.001). Finally, most beneficiaries (96.9% in 2014) received a targeted medication review, regardless of whether a CMR was offered or provided.
CONCLUSION: More than 4 million Medicare beneficiaries were enrolled in Part D MTM in both 2013 and 2014. However, less than 20% of eligible beneficiaries received a CMR during those years, and rates of MTP resolution were low. Future evaluation of Part D MTM delivery should examine changes in eligibility criteria and delivery over time to inform MTM policy and changes in practice.
Copyright © 2020 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31926872     DOI: 10.1016/j.japh.2019.12.002

Source DB:  PubMed          Journal:  J Am Pharm Assoc (2003)        ISSN: 1086-5802


  3 in total

1.  Effects of the Medicare Part D Comprehensive Medication Review on Racial and Ethnic Disparities in Medication Adherence.

Authors:  Xiaobei Dong; Chi Chun Steve Tsang; Shirong Zhao; Jim Y Wan; Ya-Chen Tina Shih; Marie A Chisholm-Burns; Samuel Dagogo-Jack; William C Cushman; Lisa E Hines; Junling Wang
Journal:  Am Health Drug Benefits       Date:  2021-09

2.  Effects of the Medicare Part D comprehensive medication review on medication adherence among patients with Alzheimer's disease.

Authors:  Xiaobei Dong; Chi Chun Steve Tsang; Shirong Zhao; Jamie A Browning; Jim Y Wan; Marie A Chisholm-Burns; Christopher K Finch; Jack W Tsao; Lisa E Hines; Junling Wang
Journal:  Curr Med Res Opin       Date:  2021-06-24       Impact factor: 2.705

3.  Exploring Racial and Ethnic Disparities in Medication Adherence Among Medicare Comprehensive Medication Review Recipients.

Authors:  Xiaobei Dong; Chi Chun Steve Tsang; Jim Y Wan; Yachen Tina Shih; Marie A Chisholm-Burns; Samuel Dagogo-Jack; William C Cushman; Lisa E Hines; Junling Wang
Journal:  Explor Res Clin Soc Pharm       Date:  2021-06-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.